- Home
- JKHY vs PEN Comparison
JKHY vs PEN Comparison
Compare JKHY & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JKHY | PEN |
|---|---|---|
| Founded | 1976 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 12.9B |
| IPO Year | 2000 | 2015 |
Fundamental Metrics
Financial Performance| Metric | JKHY | PEN |
|---|---|---|
| Price | $147.18 | $329.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $197.25 | ★ $357.33 |
| AVG Volume (30 Days) | ★ 732.1K | 543.5K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | 19.31 | ★ 1155.56 |
| EPS | 3.70 | ★ 4.52 |
| Revenue | ★ $1,536,603,000.00 | $1,403,665,000.00 |
| Revenue This Year | $8.03 | $14.34 |
| Revenue Next Year | $6.35 | $13.71 |
| P/E Ratio | ★ $41.47 | $72.88 |
| Revenue Growth | 7.37 | ★ 17.50 |
| 52 Week Low | $144.13 | $221.26 |
| 52 Week High | $193.39 | $362.41 |
Technical Indicators
Market Signals| Indicator | JKHY | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 28.18 | 37.63 |
| Support Level | $145.31 | $326.58 |
| Resistance Level | $164.97 | $338.99 |
| Average True Range (ATR) | 4.45 | 2.24 |
| MACD | -0.63 | -0.22 |
| Stochastic Oscillator | 2.19 | 26.14 |
Price Performance
Historical ComparisonAbout JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About PEN Penumbra Inc.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.